**Innovate UK Biomedical Catalyst Future Medicines Accelerator**

**Application Form**

Applications are invited from companies interested in benefiting from the Innovate UK Biomedical Catalyst Future Medicines Accelerator programme that meet the following criteria:

* Are a UK-based SME according to Innovate UK definitions, or an academic in the early stages of forming an SME. Note the company must be incorporated with a bank account by the end of the Accelerator which is 31st March 2026.
* Have an innovative idea to develop a novel product, technology, or process which is in scope of the “Future Medicines” sector (as defined below) and that directly impacts upon a clear evidenced and sizeable healthcare challenge.
* Are developing a technology, product, process or service with a clear and obvious route to market that will lead to a commercial opportunity.
* **We are particularly interested in companies within the Radiopharmaceuticals field.**

Future Medicines scope: The development, discovery or manufacturing of a broad range of next generation of medical treatments, technologies products, processes, or services to address increasingly complex diseases usually leveraging advanced scientific approaches allowing more targeted, effective therapies tailored to individual patient’s needs.

Examples include (but not restricted to):

* Radiopharmaceuticals
* Microbiome-based therapies
* Biopharmaceuticals
* Regenerative and Personalised Medicines
* Gene Therapies
* CAR-T Cell Therapies

Please note that the **development of long-acting therapeutics is out of scope**.

Any information provided in this application must be **non-confidential**. By completing and submitting the application you agree to the Terms and Conditions as detailed below. All applications should be uploaded to form on this web page: <https://lyvalabs.com/future-medicines-apply>

You will receive an email reply confirming your application. Applicants will then be contacted by 13th October to inform them whether they have been successful or unsuccessful.

Any queries or withdrawals should be directed to [futuremedicines.accelerator@lyvalabs.com](mailto:futuremedicines.accelerator@lyvalabs.com) with the subject line of ‘Innovate UK Future Medicines Application’.

**The deadline for submission is midday on 26th September 2025.**

|  |  |
| --- | --- |
| **You and your company** | |
| Applicant Contact Name: |  |
| Job Title: |  |
| Company/Institution Name: |  |
| Contact Address / Postcode: |  |
| Contact e-mail: |  |
| Contact phone: |  |
| Website (if applicable): |  |
| Date company was established: |  |
| Stage of incorporation of your business: |  |
| Status of the IP. Is it owned/licensed by the company? If not, please expand. |  |
| Does the company have a bank account? If not, when will this be opened? |  |
| Number of employees: |  |
| Turnover in last financial year’s accounts: |  |
| Details of funding raised to date: |  |

|  |
| --- |
| **Your proposition** |
| **Q1. Provide a summary of your company (200 words max):** *Please include, what your company does, the technology/product/service that is being developed, your business model and how you this fits the scope of the Accelerator (200 words max)* |
| **Q2. What is the business opportunity? (400 words max):** *Please describe, the problem you are trying to solve and the size of it, how you know it’s a problem (i.e. have you spoken to customer/end-users?), who are your competition and what are their limitations/market failures?* |
| **Q3. What is your solution and how is it innovative? (500 words max):**  *Please describe technology/product/process/service, detailing how it is innovative, progress to date and the technical challenges which remain. Include details on IP and freedom to operate.* |
| **Q4. What is the market opportunity? (300 words max):**  *Please describe market opportunity/size, your route to market (include regulatory considerations), how you will grow your business and any barriers to market entry.* |
| **Q5. Describe your business journey (200 words max):** *Summarise progress to date (including technology readiness level), anticipated funding requirements and milestones for next 12-24 months and how this helps with the long-term business vision.* |
| **Q6. The Team (200 words max):** *Describe key team members, their roles and relative experience. Include any gaps you are aware of and how you intend to fill these.* |
| **Q7. Effects of EDI, Environment and Sustainability (300 words max):** *Please describe how EDI, environmental and sustainability have been considered in your product development and how this approach addresses inequalities.* |
| **Q8. Benefits of Accelerator (100 words max):** *Please describe how the programme will help you and your business and what you expect to get out of it.* |

**Terms and Conditions**

Any information provided in this application must be non-confidential. By completing and submitting the application you agree to the Terms and Conditions as detailed below.

All information provided will be treated in confidence and only distributed for use in the selection and delivery of the programme. The process will be competitive, and the decision of the panel will be by majority and is final.

Following the closing date, applications received will be assessed by a small panel of assessors with relevant technical and commercial expertise.

Questions 1-6 above will be scored by the panel who will judge each question, questions 7 & 8 will not be scored but may be considered when assessing applications, particularly when scores are tied.

The panel will select around 30 applications that will get the opportunity to proceed to the next stage of the Innovate UK Future Medicines programme – the pre-accelerator modules. Applicants will be contacted by **13th October** to inform them whether they have been successful or unsuccessful.

The 30 successful applicants selected for the programme must be available to attend a Pre-Accelerator meet-up on **12th November 2025** and 5 days of compulsory pre-Accelerator training taking place between **1st November 2025 and 19th December 2025**.

The small panel of assessors with relevant technical and commercial expertise will also select up to 20 organisations to receive the bespoke Accelerator support. The exact timing of this will be agreed between the successful organisations and the expert providers of the bespoke training elements of the programme. This element of the program will take place between **1st January and 31st March 2026**.

For the purpose of the Data Protection Act 1998, LYVA Labs is a Data Controller. To process your application, we may collect and process data that you have provided in your application, including your name, address, email address, current job role, and details of your innovation. Please see above for how and with whom we will share your application and your data contained within the application.

Applications will be non-confidential, and we will treat them as confidential as far as is reasonably possible. In case of any mutual desire between an applicant and a partner organisation or expert provider to the programme to exchange confidential information, the applicant and the other party shall execute an appropriate confidentiality agreement. Participants are responsible for seeking their own legal advice without any liability to the providers of the Biomedical Catalyst Future Medicines Accelerator.